The exploratory study on change of the gutmicrobiota in Rabeprazole divided doses:Direction crossover controlled trial in front of an open label

The exploratory study on change of the gutmicrobiota in Rabeprazole divided doses:Direction crossover controlled trial in front of an open label - The exploratory study on change of the gutmicrobiota in the Rabeprazole administration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032040

Enrollment

Registered

2018-04-01

Start date

2018-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux esophagitis.

Interventions

Subjects are 12 Helicobacter pylori infection-negative healthy Volunteers.Subjects take rabeprazole 10 mg o.d for 7 days. We conduct examination of 24 hours pH monitoring and flora sampling on the sev

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.With consent 2.From 20 years old to 50 years old. 2.H.pylori infection-negative. 3.Performance status:ECOG 0.

Exclusion criteria

Exclusion criteria: 1.No consent 2.With the drug including a suppressant acid-secreting for the past one month. 3.With probiotics (medicine for intestinal disorders) or the antimicrobial agent for the past one month. 4.With grapefruits for the past two weeks. 5.With operating treatment for upper gastrointestinal disease including esophagus and stomach. 6.During pregnancy or nursing.

Design outcomes

Primary

Measure	Time frame
Correlation of intragastric pH and enteric bacteria profile.	—

Countries

Japan

Contacts

Public ContactMitsushige Sugimoto

Shiga University of Medical Science Hospital Division of Digestive Endoscopy

sugimo@belle.shiga-med.ac.jp077-548-2618

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026